Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
11 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
0.2877
-0.0023 (-0.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc Announces Corporate Restructuring plan
January 25, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
January 23, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
January 18, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
January 09, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
January 05, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
December 14, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
December 07, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
November 29, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
November 15, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
November 08, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
November 07, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Wellution™ Signs an Agreement with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms
November 01, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
October 28, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
October 12, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
September 30, 2022
From
SciSparc Ltd
Via
GlobeNewswire
Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.
July 07, 2022
NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a...
From
Traders News Source
Via
AccessWire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
June 29, 2022
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...
Via
FinancialNewsMedia
Central Nervous System (CNS) Therapeutics Global Market Expected to Reach $154 Billion By 2027
June 09, 2022
Palm Beach, FL – June 9, 2022 – FinancialNewsMedia.com News Commentary – The central nervous system (CNS) consists of the brain and spinal cord and brain and nervous system problems are more common and...
Via
FinancialNewsMedia
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
June 07, 2022
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still...
Via
FinancialNewsMedia
Exposures
COVID-19
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).
June 02, 2022
NEW YORK, NY / ACCESSWIRE / June 2, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).
From
Aegis Capital Corp.
Via
AccessWire
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
May 26, 2022
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...
Via
FinancialNewsMedia
Exposures
COVID-19
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
May 24, 2022
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster...
Via
FinancialNewsMedia
SciSparc Has Been Granted The Patent in the United States for its Core Technology, Used to Treat Central Nervous System Disorders.
January 06, 2022
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Advances for Tourette Syndrome, Alzheimer’s Disease, Pain Management, Autism Spectrum Disorder and Epilepsy from Proprietary Compounds: SciSparc Ltd. (NASDAQ: SPRC)
January 05, 2022
Via
Get News
Pharmaceutical company SciSparc Ltd to make progress in treating nervous system disorders in 2022
January 04, 2022
Via
AB Newswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.